Optimal blood pressure for a patient with type 2 diabetes mellitus: Insight from the accord study

Current Hypertension Reports

Volumn 12, Issue 5, 2010, Pages 313-315

  Weir, Matthew R ^a   Bakris, George L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

EID: 77958466447     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0145-z     Document Type: Note

References (4)

1. J Stamler O Vaccaro JD Neaton D Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 434 444 1:STN:280: DyaK3s7mtFyrtQ%3D%3D 10.2337/diacare.16.2.434 8432214
2. ACCORD Study Group, Ginsberg HN, Elam MB, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
3. P Sleight J Redon P Verdecchia, et al. 2009 Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study J Hypertens 27 1360 1369 1:CAS:528:DC%2BD1MXnsVyis7g%3D 10.1097/HJH.0b013e32832d7370 19506526
4. CJ Pepine EM Handberg RM Cooper-DeHoff, et al. 2003 A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2805 2816 1:CAS:528: DC%2BD3sXps1Crurk%3D 10.1001/jama.290.21.2805 14657064 (Pubitemid 37509488)